Skip to main content
Equibles
AVXL logo

AVXL · Anavex Life Sciences Corp.

Track AVXL — free

Use AVXL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about AVXL

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.22 -0.05 (-1.53%) At close · Aug 14
Market Cap
$298.40M
Shares
92.67M

Anavex Life Sciences Corp. Earnings Call Transcripts

Every quarterly earnings call for Anavex Life Sciences Corp. (AVXL) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q1
2026-02-09
Anavex Life Sciences Corp. Q1 FY2026 Earnings Call
Positive tone Blarcamesine for early Alzheimer's disease Scientific publications and presentations FDA Type C meeting feedback
Diluted EPS
$-0.06
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-11-25
Anavex Life Sciences Corp. Q4 FY2025 Earnings Call
Positive tone Long-term Blacaramazine clinical efficacy data ANAVEX 371 schizophrenia Phase 2 results Precision medicine / genetic subpopulations (ABCLEAR)
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-06-30
Anavex Life Sciences Corp. Q3 FY2025 Earnings Call
Confident tone Blarcamesine / ANAVEX 2-73 in Alzheimer's EMA regulatory review Rett syndrome program
Diluted EPS
$-0.16
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-03-31
Anavex Life Sciences Corp. Q2 FY2025 Earnings Call
Confident tone Blarcamesine for Alzheimer's disease Schizophrenia program (ANAVEX3-71) EMA regulatory review
Diluted EPS
$-0.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2024-12-31
Anavex Life Sciences Corp. Q1 FY2025 Earnings Call
Confident tone Blarcamesine for Early Alzheimer's Disease European Regulatory Review (EMA) Comparison to Monoclonal Antibodies (Kisunla/donanemab)
Diluted EPS
$-0.14
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-09-30
Anavex Life Sciences Corp. Q4 FY2024 Earnings Call
Confident tone Blacamasent EMA MAA acceptance for Alzheimer's Attention AD/OLE long-term data and publication Blacamasent clinical efficacy and mechanism of action
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q2
2024-05-09
Anavex Life Sciences Corp. Q2 FY2024 Earnings Call
Confident tone Blarcamesine (ANAVEX®2-73) in Alzheimer's Disease ANAVEX®3-71 in Schizophrenia European MAA Submission
Diluted EPS
$-0.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-09-30
Anavex Life Sciences Corp. Q4 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-06-30
Anavex Life Sciences Corp. Q3 FY2023 Earnings Call
Diluted EPS
$-0.14
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-03-31
Anavex Life Sciences Corp. Q2 FY2023 Earnings Call
Diluted EPS
$-0.17
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2022-12-31
Anavex Life Sciences Corp. Q1 FY2023 Earnings Call
Diluted EPS
$-0.17
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-09-30
Anavex Life Sciences Corp. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-06-30
Anavex Life Sciences Corp. Q3 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-03-31
Anavex Life Sciences Corp. Q2 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2021-12-31
Anavex Life Sciences Corp. Q1 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-09-30
Anavex Life Sciences Corp. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-06-30
Anavex Life Sciences Corp. Q3 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-03-31
Anavex Life Sciences Corp. Q2 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2020-12-31
Anavex Life Sciences Corp. Q1 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-28
Anavex Life Sciences Corp. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-06-30
Anavex Life Sciences Corp. Q3 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–21 of 21 earnings calls
Key facts CIK 1314052 CUSIP 032797300 13F (30d) 167 filings 165 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)